KDR and thyroid gland carcinoma: AMG 706 (a novel oral inhibitor of VEGFR, platelet-derived growth-factor receptor, and KIT) was used in the treatment (125 mg administered orally once daily) of 93 patients with progressive, locally advanced or metastatic, radioiodine-resistant differentiated thyroid cancer.